Repros Receives FDA Guidance Regarding Clinical Program for Androxal
October 22, 2013 at 22:13 PM EDT
Repros Therapeutics (NASDAQ: RPRX ) today reported it has received guidance from the FDA regarding its clinical program for Androxal. The Company had previously submitted a list of questions with the final clinical study report for ZA-301. Repros subsequently provided an update of topline results from ZA-302 to the FDA. The
